15th International Symposium on Anti-Angiogenic Therapy 2013

Jan 18, 2013

January 2013, La Jolla, California
Abstract: Antivascular activity of RRx-001 in SCCVII and U87 tumors

Abstract: RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA)

Abstract: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent